Intelligent Migraine Treatment System
Legal Citation
Summary of the Inventive Concept
A novel system integrating IoT, AI, blockchain, and novel materials to optimize migraine treatment with ubrogepant, enhancing patient outcomes and improving treatment efficacy.
Background and Problem Solved
The original patent disclosed methods for treating migraine with ubrogepant, but these methods lacked real-time monitoring, personalized dosing, and secure data tracking. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system.
Detailed Description of the Inventive Concept
The system comprises a wearable IoT device monitoring physiological parameters, a blockchain-secured database storing said parameters, and a method for administering ubrogepant based on said parameters. AI-driven analysis of patient data and wearable sensor inputs optimizes ubrogepant dosing and administration timing. A mobile application utilizing machine learning algorithms predicts migraine onset, and a wearable device administers ubrogepant in response to said prediction. A blockchain-based ledger tracks ubrogepant administration, and an AI-driven analytics platform provides insights on treatment outcomes. A novel material-based transdermal patch enables efficient ubrogepant delivery.
Novelty and Inventive Step
The integration of IoT, AI, blockchain, and novel materials with ubrogepant treatment is new and non-obvious, providing a synergistic combination that enhances patient outcomes and improves treatment efficacy.
Alternative Embodiments and Variations
Alternative embodiments include using different machine learning algorithms, integrating additional sensors, or utilizing alternative blockchain platforms. Variations may include using different migraine treatments or expanding the system to treat other neurological conditions.
Potential Commercial Applications and Market
The Intelligent Migraine Treatment System has significant commercial potential in the pharmaceutical and healthcare industries, targeting patients and healthcare providers seeking more effective and personalized migraine treatments.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Neurological treatment technologies, specifically migraine management systems involving pharmaceutical delivery, medical device integration, and digital health monitoring
Person of Ordinary Skill (PHOSITA) Profile
A professional with expertise in biomedical engineering, pharmaceutical sciences, and digital health technologies, possessing knowledge of IoT medical devices, machine learning applications in healthcare, and drug delivery mechanisms
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring technologies with established pharmaceutical treatments represents a predictable evolution in personalized medicine. The combination of ubrogepant administration with IoT and AI-driven monitoring follows established technological trends in precision healthcare. The disclosed system represents a logical extension of existing migraine treatment methodologies by leveraging contemporary digital health technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,542 |
|---|---|
| Title | Treatment of migraine |
| Assignee(s) | Allergan Pharmaceuticals International Limited |